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Background: We have previously shown a sprouting of sympathetic fibers into the upper dermis of the skin following
subcutaneous injection of complete Freund’s adjuvant (CFA) into the hindpaw. This sprouting correlated with an increase
in pain-related sensitivity. We hypothesized that this sprouting and pain-related behavior were caused by an increase
in nerve growth factor (NGF) levels. In this study, we investigated whether the inhibition of mature NGF degradation,
using a matrix metalloproteinase 2 and 9 (MMP-2/9) inhibitor, was sufficient to reproduce a similar phenotype.
Results: Behavioral tests performed on male Sprague–Dawley rats at 1, 3, 7 and 14 days after intra-plantar MMP-2
/9 inhibitor administration demonstrated that acute and chronic injections of the MMP-2/9 inhibitor induced
sensitization, in a dose dependent manner, to mechanical, hot and cold stimuli as measured by von Frey filaments,
Hargreaves and acetone tests, respectively. Moreover, the protein levels of mature NGF (mNGF) were increased,
whereas the levels and enzymatic activity of matrix metalloproteinase 9 were reduced in the glabrous skin of the
hind paw. MMP-2/9 inhibition also led to a robust sprouting of sympathetic fibers into the upper dermis but there
were no changes in the density of peptidergic nociceptive afferents.
Conclusions: These findings indicate that localized MMP-2/9 inhibition provokes a pattern of sensitization and
fiber sprouting comparable to that previously obtained following CFA injection. Accordingly, the modulation of
endogenous NGF levels should be considered as a potential therapeutic target for the management of
inflammatory pain associated with arthritis.
Keywords: Matrix metalloproteinase, Nerve growth factor, Allodynia, Hyperalgesia, Sympathetic sproutingBackground
Nerve growth factor (NGF) is the prototype of the
neurotrophin family of growth factors [1,2]. As a trophic
factor, NGF supports the development and survival of
peptidergic primary sensory and sympathetic neurons
[3]. During early neuronal development, it has a critical
role in the survival and growth of sympathetic and sen-
sory neurons [4-6]. Though NGF is no longer required
for the survival of sensory neurons in adult animals, a
body of evidence has shown that NGF continues to be* Correspondence: alfredo.ribeirodasilva@mcgill.ca
†Equal contributors
1Department of Pharmacology and Therapeutics, McGill University, 3655
Prom Sir-William-Osler, Montreal, QC H3G 1Y6, Canada
2Department of Anatomy and Cell Biology, McGill University, Montreal, QC
H3A 2B2, Canada
Full list of author information is available at the end of the article
© 2013 Osikowicz et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the orinvolved in specifying the function of many sensory neu-
rons and their interactions with sympathetic neurons [7].
Within the mature organism, NGF plays a significant role
in mediating inflammatory and immune responses after
peripheral tissue injury [8]. NGF levels are elevated in sev-
eral conditions associated with pain in humans, including
arthritis [9,10], cystitis [11,12] and chronic headaches [13].
In animal studies, the concentration of NGF in the skin
increases in response to inflammation produced by either
injection of irritants [12] or ultraviolet-B irradiation [14].
NGF has been implicated in the sensitization of peripheral
nerves to noxious stimuli [15,16].
It has recently been shown by Bruno and Cuello
(2006) that NGF is released as a precursor, proNGF, and
not in the the growth-promoting form, mature NGF
(mNGF) [17]. This work revealed a protease cascaderal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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degradation in the extracellular space. One of the key
regulatory enzymes involved in proNGF processing
within the CNS is plasmin, which is converted from
plasminogen by tissue plasminogen activator (tPA) or
urokinase plasminogen activator (uPA). In the above re-
port it was proposed that this newly reported metabolic
pathway should have an impact on pain mechanisms.
However, the validation of this pathway in the periphery
and its impact on pain regulation remains unresolved.
This biochemical pathway might be particularly relevant
for pain because NGF over-expression studies have
shown that NGF is an important signal for mechanical
and thermal sensitization [16]. Based on the above, we
have advanced the hypothesis that interfering with the
levels of endogenous mNGF by modulating its formation
from proNGF should provide an attractive opportunity
to develop a novel class of agents for the treatment of
pain. In the present study we aim at exploring whether
NGF processing within the periphery is analogous to
that already shown in the CNS of naive rats. As a proof
of concept, we sought to verify whether the inhibition of
endogenous NGF degradation in naïve rats — by the ad-
ministration of a matrix metalloproteinase 2 and 9
(MMP-2/9) inhibitor — influenced: 1) the protein levels
of molecules involved in NGF processing, 2) the innerv-
ation patterns of the skin by sensory and autonomic
fibers as well as relationship between them, and 3) the
pain thresholds.
Results
Effect of repeated administration of the MMP-2/9
inhibitor on the protein levels of NGF and MMP-9
Western blot analyses of the glabrous skin samples were
carried out on the 14th day after two weeks of chronic
injections of the MMP-2/9 inhibitor - 20 μg, intraplantar
(i.pl.). This time point and dose for biochemical analyses
were selected on the basis of behavioral experiments
(described below) where the maximum effect on pain-
related behavior was observed on the 14th day of re-
peated injections of the MMP-2/9 inhibitor at a dose of
20 μg. Both proNGF, mNGF and MMP-9 were identified
based on their molecular weights; proNGF migrated
close to 40 kDa, mNGF migrated at 14 kDa, and MMP-
9 migrated at 92 kDa. The localization of these bands is
consistent with what is described in other publications
using the same antibodies [17-19]. Furthermore, they
aligned with the corresponding bands from positive con-
trols (mouse submandibular gland extracts for NGF and
kidney homogenates for MMP-9) (data not shown). Our
data revealed an increase in the protein levels of the ma-
ture form of NGF (mNGF) in the ipsilateral paw as com-
pared to the contralateral paw (shown as an interrupted
line on the graphs, 0.62 ± 0.06 vs 0.33 ± 0.02; Figure 1A)and also when compared to ipsilateral paw samples from
vehicle-treated rats (0.62 ± 0.06 vs 0.36 ± 0.01). No sig-
nificant changes in the protein levels of the precursor
form of NGF (proNGF) were detected by Western blot
analysis in the ipsilateral paw as compared to the results
from the contralateral paw (0.71 ± 0.14 vs 0.59 ± 0.03;
Figure 1B) and to the ipsilateral paw of vehicle-treated
rats (0.71 ± 0.14 vs 0.62 ± 0.05). In addition, the treat-
ment with the MMP-2/9 inhibitor resulted in the de-
crease of MMP-9 protein levels in the ipsilateral paw
when compared to the contralateral side (0.38 ± 0.04 vs
0.61 ± 0.03; Figure 1C) and when compared to the ipsi-
lateral paw of vehicle-treated rats (0.38 ± 0.04 vs 0.62 ±
0.01). To validate this observation, we pre-treated the
samples with urea, a strong denaturing agent that pro-
motes protein unfolding [20]. This treatment ensured
that the primary antibody against MMP-9 was in fact
recognizing its antigenic site and that the binding was
not being masked by the MMP-2/9 inhibitor binding. In-
deed, we did not find any difference in the data after
urea pre-treatment, an observation that provides suffi-
cient evidence that the protein level is in fact decreased
(data not shown).
Effect of repeated administration of the MMP-2/9
inhibitor on the enzymatic activity of MMP-9
Zymography analyses performed on the glabrous skin
samples from the hind paws revealed changes in the en-
zymatic activity of both MMP-9 (82-kDa) and MMP-2
(65-kDa) following the daily subcutaneous administra-
tion of MMP-2/9 inhibitor (20 μg, i.pl.; Figure 2A, B).
The treatment with the MMP-2/9 inhibitor reduced the
enzymatic activity of MMP-9 and MMP-2 in the ipsilat-
eral paw when compared to the contralateral paw
(shown as an interrupted line on the graphs, 0.57 ± 0.03
vs 1.14 ± 0.05 and 0.72 ± 0.04 vs 0.94 ± 0.06, respectively)
and when compared to ipsilateral skin samples from
vehicle-treated rats (0.57 ± 0.03 vs 1.0 ± 0.06 and 0.72 ±
0.04 vs 1.0 ± 0.06, respectively).
Effect of the repeated administration of MMP-2/9
inhibitor on the skin innervation pattern
In the current study, we hypothesized that inhibition of
MMP-9 in naïve animals would prevent the degradation
of endogenous mNGF and lead to sympathetic fiber
sprouting in the skin. Indeed, there was an invasion of
the upper dermis by sympathetic fibers, as detected by
VMAT-2 immunoreactivity, in skin samples from ani-
mals treated for 2 weeks with daily injections of MMP-2
/9 inhibitor (Figure 3). The increased number of sympa-
thetic fibers in the scanned area of the upper dermis was
statistically significant at doses of 20 and 40 μg of MMP-
2/9 inhibitor. Interestingly, the density of peptidergic
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Figure 1 MMP-2/9 inhibitor administration altered the protein levels of NGF and MMP-9 in the skin of naive rats. Western blot analysis
performed on the glabrous skin samples following 14 days of repeated MMP-2/9 inhibitor (MMP-2/9I.; 20 μg, i.pl.) administration showed a
significant increase in the protein levels of mature NGF (mNGF) (A), with no influence on the protein level of the precursor proNGF (B). Repeated
administration of MMP-2/9I. (20 μg, i.pl.) significantly reduced the protein levels of MMP-9 (C) in the glabrous skin. Examples of representative
western blots are presented in the upper panels A, B and C. The densitometry results are presented as the mean ± SEM from all samples. Inter-
group differences were analyzed by ANOVA with a Bonferroni’s multiple comparison test. ***p < 0.001 indicates a significant difference as
compared to glabrous skin sample of chronic vehicle-treated (V) naive rats. The interrupted line on the graphs indicates protein analyses for
mNGF, proNGF or MMP-9 in the contralateral glabrous skin of chronic MMP-2/9I.-treated naïve rats.
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One interesting observation in MMP-2/9 inhibitor
treated animals was that, in the upper dermis, the
VMAT-2-immunoreactive fibers were often observed
wrapping around CGRP-IR fibers (Figure 5).
Effect of a single administration of the MMP-2/9 inhibitor
on allodynia and hyperalgesia
A single subcutaneous i.pl. administration of matrix






























Figure 2 Effect of MMP-2/9 inhibition on the enzymatic activity of MM
following repeated MMP-2/9 inhibition (MMP-2/9I.; 20 μg, i.pl.), zymography w
revealed reduction in the enzymatic activity of both MMP-9 (A) and MMP-2 (B
panels A and B. The densitometry results are presented as the mean ± SEM. In
multiple comparison test. *p < 0.05, ***p < 0.001 indicate a significant differen
interrupted line on the graphs indicates zymogram analyses for MMP-9 and M
naïve rats.allodynia in naive rats, as measured by the von Frey test.
Pain-related behavior was evaluated at 30, 60, 180 minutes
and 24 hours after single injection of this inhibitor
(Figure 6A). The MMP-2/9 inhibitor (20 μg; i.pl.) induced
thermal hyperalgesia as measured by the Hargreaves test
at 60 minutes following a single injection (Figure 6B). In
contrast, a single injection of the MMP-2/9 inhibitor (10,
20, 40 μg) did not influence cold allodynia as assessed by
the acetone test at 30, 60, 180 minutes and 24 hours after





























P-9 and MMP-2 in the skin of naive rats. To evaluate MMP activity
as performed on extracts from glabrous skin samples. The analysis
). Examples of representative zymograms are presented in the upper
ter-group differences were analyzed by ANOVA with a Bonferroni’s
ce as compared to glabrous skin sample of vehicle-treated (V) rats. The
MP-2 in the contralateral glabrous skin of chronic MMP-2/9I.-treated
Figure 3 Changes in sympathetic fiber innervation in the skin of naïve rats following MMP-2/9 inhibition. A and B represent confocal
images of the rat’s glabrous hindpaw skin in vehicle-treated and MMP-2/9 inhibitor (MMP-2/9I.; 20 μg, i.pl.) injected rats, respectively, at the
2 week end point. Note an invasion of sympathetic fibers into the upper dermis (B), mimicking what we had previously observed in a model of
inflammatory arthritis [35]. This fiber population was not normally found in control (vehicle-treated) animals as shown in A. Arrows in B indicate
VMAT2-IR fibers in the upper dermis. The results in C are from all experimental groups and presented as the mean ± SEM. Inter-group differences
were analyzed by ANOVA with a Dunnett’s post hoc test. *p < 0.05, **p < 0.01 indicates a significant difference as compared to glabrous skin
sample of chronic vehicle-treated (V) naive rats. The dashed lines represent the dermal-epidermal junction.
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inhibitor on allodynia and hyperalgesia
The repeated administration of MMP-2/9 inhibitor (10,
20, 40 μg; i.pl.) to naïve rats once a day for two weeks
resulted in the development of hypersensitivity to both
mechanical and thermal stimuli as measured by the von
Frey, Hargreaves and acetone tests, respectively (Figure 7).
The sensitivity to both mechanical and thermal stimuli in-
creased over time. The analysis of the area under the
curve (AUC), which allows for the assessment of the glo-
bal effect of treatment, shows that the MMP-2/9 inhibitor
treatment induced a significant allodynia and hyperalgesia
in naïve rats (p < 0.05) (Figure 7A,B,C; right panels). We
did not observe any visible signs of inflammation (redden-
ing or swelling of the skin) throughout the 14 days period
at the MMP-2/9 inhibitor or vehicle injection site. More-
over, we found a statistically significant positive correlation
between the number of sympathetic fibers in the upper
dermis of the skin and mechanical allodynia, as measured
by the von Frey test (p = 0.0029), and with cold allodynia,
as measured with the acetone test (p = 0.0086). There wasno positive correlation between the thermal hyperalgesia
measured by the Hargreaves test and the sympathetic
sprouting, although there was trend (p = 0.08).
Discussion
The present study provides evidence that the intra-
plantar administration of an MMP-2/9 inhibitor induced
sensitization to mechanical, heat and cold stimuli in
naïve rats. Our data also shows that the protein levels of
mNGF and MMP-9 were affected in the hind paw skin
following repeated MMP-2/9 inhibitor injections. Fur-
thermore, we found that the MMP-2/9 inhibitor induced
sprouting of sympathetic fibers into the upper dermis in
the glabrous hind paw skin, but no change in the density
of sensory peptidergic fibers. Our results support the hy-
pothesis that sympathetic sprouting and pain related-
behavior are due to an increase in mNGF levels.
NGF metabolic pathway
NGF is secreted from cells in an activity dependent
manner as a precursor (proNGF), together with a full
Figure 4 Density of sensory fibers in the skin of naïve rats following matrix MMP-2/9 inhibition. The density of CGRP-positive fibers
following repeated matrix MMP-2/9 inhibitor (MMP-2/9I.; 10, 20, 40 μg, i.pl.) administration did not change significantly from control levels (C). A
and B are representative confocal images of the rat’s glabrous hindpaw skin in vehicle-treated and MMP-2/9 inhibitor (MMP-2/9I.; 20 μg, i.pl.)
injected rats, respectively. The results are presented as the mean ± SEM. Inter-group differences were analyzed by ANOVA with a Dunnett’s post
hoc test. The dashed line represents the dermal-epidermal junction.
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into the mature (active) form and its degradation [17].
The existence of the CNS protease cascade responsible
for the conversion of proNGF into mNGF and for its
degradation was demonstrated by a series of ex vivo asFigure 5 Sympathetic/sensory fiber interaction in the skin of naïve ra
ectopic sympathetic fibers (VMAT2-IR) with peptidergic nociceptive fibers (
following repeated injections of MMP-2/9 inhibitor (MMP-2/9I.; 20 μg, i.pl.).
in vehicle-treated and MMP-2/9 inhibitor (MMP-2/9I.; 20 μg, i.pl.) injected rawell as in vivo studies [17] that defined the relevance of
tPA/plasminogen activation in the proNGF to mNGF
conversion and of MMP-9 in the enzymatic degradation
of mNGF. Although this NGF metabolic pathway is now
well established in the CNS [18,21], it has been muchts following MMP-2/9 inhibition. Note that close appositions of
CGRP-IR) in the upper dermis were observed at the 2 week end point

























































































Figure 6 Effect of a single MMP-2/9 inhibitor administration on
allodynia and hyperalgesia in naive rats. A single intra-plantar
administration of MMP-2/9 inhibitor (MMP-2/9I.; 10, 20, 40 μg, i.pl.)
induced mechanical allodynia and thermal hyperalgesia as measured
by von Frey and Hargreaves tests. However, the treatment had no
effect on cold allodynia as measured by acetone test. Behavior: the
von Frey (A), Hargreaves (B) and acetone (C) tests were performed
30, 60, 180 min and 24 h after MMP-2/9 inhibitor administration.
Results are presented as the mean ± SEM (n = 6–8 rats/group). Inter-
group differences were analyzed by Bonferroni’s multiple
comparison test. *p < 0.05, **p < 0.01, ***p < 0.001, compared to
vehicle-treated (V) naïve rats.
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studies arise from the fact that up-regulation of NGF is
a cause of many clinical conditions associated with pain
[9-12,22-25]. Therefore, understanding the mechanism
underlying NGF processing and its eventual modulation
provides attractive therapeutic opportunities. Our results
provide for the first time an important validation in theperiphery of the role of MMP-9 in the mNGF degrad-
ation. Indeed, we were able to show that repeated intra-
plantar administration of an MMP-2/9 inhibitor resulted
in elevated levels of mNGF in the hind paw skin. Inter-
fering with the degradation of endogenous mNGF was
also sufficient to induce sprouting of sympathetic fibers
in the skin and hypersensitivity to both mechanical and
thermal stimulation. Our results confirm and expand the
hypothesis that NGF plays an important role in pain
mechanisms (see below).
NGF induced fiber sprouting
NGF is a crucial neurotrophin for the definition of the
innervation pattern of the skin during development [26].
Adult sympathetic fibers are regulated by NGF in what
regards their survival and phenotypic maintenance
[27,28] and can respond with fiber outgrowth to supple-
mental NGF [29-32]. In the present study, we were able
to show that inhibition of MMP-9 leads to an increase
in mNGF levels and, likely as a consequence, to pain-
related behaviors and a sprouting of sympathetic fibers
into the upper dermis, a region of skin which is normally
devoid of this fiber population. Interestingly, we did not
observe any changes in the density of peptidergic sen-
sory fibers following MMP-2/9 inhibitor injections. It
has been demonstrated that sympathetic fibers are more
responsive to NGF in the adult as they depend on it for
survival, although NGF still plays a role in maintaining
the phenotype of sensory peptidergic neurons [33,34].
Therefore, the lack of peptidergic sprouting in the
current study would suggest that the levels of mNGF in
the skin resulted from MMP-2/9 inhibition were lower
than in the chronic inflammation model [35]. This is to
be expected, because following a local subcutaneous in-
jection of CFA there is extensive and long lasting skin
inflammation which likely leads to sustained elevated
local levels of mNGF. In the present study, we demon-
strate that preventing the degradation of the NGF in the
absence of any pathology is sufficient to increase the
levels of endogenous mNGF. We have also observed
that, in such conditions, the sympathetic fibers sprouted
in a pattern comparable to what we previously observed
in the arthritis model [35] and also in neuropathic pain
models [36,37]. These studies demonstrate that the ec-
topic sympathetic fibers are not associated with blood
vessels and often wrap around sensory peptidergic fibers
suggesting enhanced sympathetic-sensory interaction.
Under normal physiological conditions, the sympathetic
nervous system is not associated with nociception and
uninjured primary sensory nerve endings are not sensi-
tive to catecholamines. However, noradrenaline injection
following nerve lesions has been shown to excite small
diameter nociceptors, but not in normal conditions


















































































































Figure 7 Effect of repeated MMP-2/9 inhibition on allodynia and hyperalgesia in naive rats. Repeated intra-plantar administration of MMP-
2/9 inhibitor (MMP-2/9I.; 10, 20, 40 μg, i.pl.) once daily for fourteen days induced allodynia and hyperalgesia. Behavioral tests: the von Frey test
(A), Hargreaves test (B) and acetone test (C) were performed on the 1st, 3rd, 7th and 14th day of repeated MMP-2/9 inhibitor injections. Results
are presented as the mean ± SEM (n = 6–8 rats/group). Inter-group differences were analyzed by Bonferroni’s multiple comparison test. *p < 0.05,
**p < 0.01, ***p < 0.001, compared to vehicle-treated (V) naïve rats. The area under the curve (AUC) was calculated by the Trapezoidal & Simpson’s
Rules, Pharmacologic Calculation System, version 4.0-03/11/86. Inter-group differences were analyzed by Bonferroni’s Multiple Comparison Test.
*p < 0.05, **p < 0.01, ***p < 0.001 indicate a significant difference as compared to chronic vehicle-treated (V) naive rats.
Osikowicz et al. Molecular Pain 2013, 9:37 Page 7 of 13
http://www.molecularpain.com/content/9/1/37participation in some forms of neuropathic pain [40].
One possible mechanism for the role of the sympathetic
system in pathological pain is the ectopic association of
sympathetic fibers with sensory peptidergic fibers in
upper dermis of the skin [37,41]. Curiously, a similar ec-
topic association of sensory and sympathetic fibers was
also observed in the thick skin of the rat hind paw fol-
lowing chronic inflammation [35]. We observed here a
similar fiber remodeling which paralleled the pain-like
behavior following MMP-9 inhibition, in the absence of
any lesion. Additionally, our results concur with previ-
ous studies showing that sympathetic sprouting isrelated to increased levels of NGF. Thus, it has been
shown that intraventricular infusion of nerve growth fac-
tor per se is able to induce sympathetic fiber sprouting
in the sensory ganglia [42], subpial region of the me-
dulla, spinal cord [43] and in the intracranial vasculature
[44,45] of naïve rats. Conversely, surgical or chemical
sympathectomy has been shown to reduce the thermal
and mechanical hyperalgesia evoked by NGF [9,46,47].
NGF-evoked hyperalgesia
It has been shown that exogenous treatment with NGF
evoked nociceptive behavior in animals [46,48-51] and
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into the skin induced long-lasting mechanical and thermal
hypersensitivity in humans [54,55]. Also, recently pub-
lished data obtained in the rodent reported that the intra-
plantar injection of NGF induced an immediate, long-
lasting increase in mechanical and thermal sensitivity, as
early as one hour post-injection [56]. This study reported
that the effect on thermal sensitivity was of shorter dur-
ation compared with that on mechanical sensitivity, what
is in agreement with our results and indicates that mech-
anical hypersensitivity requires a considerable longer time
to resolve than the heat hypersensitivity. This situation is
similar to that in the human, where heat hypersensitivity
resolved much faster than the long-lasting increase in
mechanical sensitivity [56]. In the current study, we ob-
served changes in pain-related behavior when we inhibited
NGF degradation in naïve rats, with a different time
course for mechanical and thermal sensitivities. The tem-
poral differences in resolution between mechanical and
thermal sensitivity suggest different mechanisms, however
what drives these differences is still unclear. One of the
possible mechanisms involved in NGF-induced hyperalge-
sia might be through sympathetic sprouting and abnormal
sympathetic-sensory interactions [57,58]. Indeed, sympa-
thetic fibers express trkA receptors and their activation re-
sults in noradrenaline release which would increase in
excitability and spontaneous activity of petidergic sensory
neurons [57,58]. Also ATP, a co-transmitter released from
sympathetic fibers and damaged tissues [59,60], has been
shown to play a role in activating primary afferents via
purinergic receptors [61] and may play a role in the
hyperexcitability as well. Recent data from our laboratory
provided some support to these sympathetic-sensory in-
teractions in an inflammatory arthritis animal model, in
which there is sympathetic fiber sprouting in skin over the
joints as well as in the arthritic joint. Indeed, in that study
we have shown that pharmacological suppression of sym-
pathetic fiber function with systemic guanethidine signifi-
cantly decreased the pain-related behavior associated with
inflammatory arthritis [62]. Our data following guanethi-
dine administration was comparable with that obtained in
other chronic pain models [63,64]. Moreover, there is also
evidence from the literature that the sodium channel Nav
1.8, expressed on sensory neurons, may be a major player
in NGF-induced thermal hyperalgesia [65]. Evidence
shows that NGF modulates this sodium channel current
density through the PKA pathway following trkA binding
[66]. These changes in sodium channels might occur even
in the absence of peptidergic fibre sprouting as conse-
quence of mNGF increases induced by MMP-2/9 inhib-
ition. Since many NGF-responsive neurons contain the
vanilloid receptor TRPV1, this receptor is also suspected
to play a role in NGF-mediated hypersensitivity [67-69].
Cultured DRG neurons treated with NGF displayenhanced inward currents in response to the application
of the TRPV1 agonist capsaicin [70,71]. NGF can increase
TRPV1 expression [72,73] and promote TRPV1 insertion
into the plasma membrane [74]. NGF also acts indirectly
by activating mast cells and neutrophils, which in turn re-
lease additional inflammatory mediators causing hyper-
sensitivity [46,47,75-77]. There is a growing body of
evidence indicating that NGF-evoked hyperalgesia is
caused by a sensitization of primary afferent nociceptors
that supply an area of damage or inflammation [78,79].
Matrix metalloproteinases have multiple functions.
Therefore, it is not surprising that there is evidence that
MMP-9 inhibition at the spinal cord level alleviates the
early phase of neuropathic pain, whereas intrathecal ad-
ministration of MMP-9 itself is sufficient to produce
neuropathic pain-like symptoms in normal animals [80].
These results at the spinal cord level are very different
from those we obtained through a peripheral inhibition
of MMP-9, likely because, in the CNS, the MMP-9-in-
duced pathophysiology involves interleukin-1β cleavage
to its active form and microglial p38 activation [80],
rather than effects through NGF. However, because
MMP-2 is also responsible for the degradation of several
pain-related mediators such as TNF-α, interleukin-1β,
and substance P [81], we cannot rule out that MMP-2
inhibition might increase the levels of these mediators
and subsequently contribute to the hyperalgesia through
a peripheral mechanim.
Conclusions
Our data provides evidence that the metabolic processing
of endogenous NGF can be modulated in the periphery in
a manner similar to what was previously demonstrated in
the central nervous system. We show that inhibition of
NGF degradation in naïve rats induces sprouting of sym-
pathetic fibers into the upper dermis of the skin, where
they wrap around the peptidergic nociceptive afferents,
suggesting an interaction between these two fiber popula-
tions. We propose that the observed sensitization to both
mechanical and thermal stimuli is a consequence of ele-
vated endogenous mNGF levels sensitizing peptidergic
primary afferents and promoting abnormal sensory-
autonomic fiber interactions in the skin. As NGF has been
strongly implicated in different pain conditions, modulat-
ing its metabolic pathway provides an opportunity to in-
fluence its endogenous levels to alleviate pain.
Methods
Animals
Adult male Sprague–Dawley rats (275–300 g) were used
in this study. Animals were housed in groups of four per
cage with sawdust bedding under a standard 12 h/12 h
light/dark cycle (lights on at 08.00 AM) with food and
water available ad libitum. All experiments were carried
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University Animal Care Committee and followed the
guidelines for animal research from the International
Association for the Study of Pain (IASP) [82].
Drug administration
An MMP-2/9 inhibitor (MMP-2/MMP-9 Inhibitor I,
EMD Chemicals, Inc.), which selectively inhibits both
MMP-2 (IC50 = 310 nM) and MMP-9 (IC50 = 240 nM),
was administered subcutaneously into the plantar region
of the right hind paw, once a day, for 14 days. The con-
trol group of rats received vehicle (DMSO, 20 mg/1 ml)
according to the same schedule. The doses of MMP-2/9
inhibitor were selected based on a previous study from
our lab [18] and our preliminary experiments. The be-
havioral tests were conducted 30, 60, 180 minutes and
24 hours after the first MMP-2/9 inhibitor injection and
then 60 min following the MMP-2/9 administration on
days 3, 7 and 14.
Behavioral tests
Signs of mechanical, heat and cold hypersensitivity were
detected using the von Frey, Hargreaves and acetone tests,
respectively. Prior to any behavioral testing, animals were
habituated three times to the testing environment. The
baseline reaction values were measured one day before the
first MMP-2/9 injection and were as follows: 26 g for the
von Frey test, 12.2 ± 1.9 s for the Hargreaves test and
0.5 ± 0.2 for acetone test.
Mechanical allodynia (von Frey test)
Mechanical allodynia in rats was measured using a series
of calibrated nylon von Frey filaments (Stoelting, Wood
Dale, IL, USA), ranging from 0.6 to 26 g. Animals were
placed in plastic cages with a wire-mesh floor. They were
placed in this environment approximately 5 min before
testing in order to allow behavioral accommodation. The
von Frey filaments were applied in ascending order to the
midplantar surface of the injured hindpaw through the
mesh floor. Each probe was applied to the foot until the
filament bent. The time interval between consecutive fila-
ment administrations was at least 5 s. The calculations
were performed as described previously [83].
Thermal hyperalgesia (Hargreaves’ test)
The pain threshold to high temperature was tested using
the Plantar Test (Hargreaves Apparatus, Ugo Basile,
Type 7370, Comerio, Varese, Italy). Rats were placed into
individual plastic cages with glass floors 5 min before
the experiment. A noxious thermal stimulus was focused
through the glass onto the plantar surface of a hind paw
until the animal lifted the paw away from the heat
source. The paw withdrawal latency was automatically
measured to the nearest 0.1 s. A cut-off latency of 20 swas used to avoid tissue damage. The latency to the
nociceptive reaction was measured in seconds under
basal condition and after drug treatment.
Thermal allodynia (acetone test)
Cold allodynia was assessed using the acetone drop
method [84]. In the test environment described above, a
50 μl droplet of acetone was applied to the midplantar
hind paw using a micropipette. Responses within the
first 20 s were scored according to the following rating
system: 0 - no response; 1- one rapid hind paw flick/
stamp; 2 - two or more hind paw flicks/stamps; 3 - pe-
riods of flicking/stamping with licking of plantar hind
paw [85]. The acetone application was repeated three
times for each hind paw, with a 3 min interval between
each application. For each rat, the sum of the three
scores was used for data analysis.
Biochemistry
Western blot
Following fourteen days of daily MMP-2/9 inhibitor ad-
ministration, the rats were decapitated and the glabrous
skin from the hind paws was collected, frozen in the li-
quid nitrogen and kept for further processing. Tissue
samples were homogenized in RIPA buffer (1% NP-40,
1% sodium deoxycholate, 0.1% sodium dodecyl sulfate,
150 mM NaCl, 25 mL Tris–HCl, pH 7.6) containing prote-
ase inhibitors (Complete, Roche Molecular Biochemicals,
Indianapolis, IN) and cleared by centrifugation (13,000 rpm
for 50 min at 4°C). Protein concentration of the super-
natant was determined using the BCA Protein Assay Kit
(Sigma). Homogenates (20 μL of 50 μg of total protein)
were resolved in 4-12% polyacrylamide gels and
transferred into a nitrocellulose membrane (Bio-Rad
Laboratories, Inc). The blots were blocked in Tris Buffer
Solution-Tween 20 (TBS-T) containing 5% non-fat pow-
dered milk at room temperature for 1 h on a rotomixer.
Nitrocellulose membranes were probed with primary anti-
bodies specific for nerve growth factor (NGF, 1:500,
E2610, Santa Cruz Biotechnology) and matrix metallo-
proteinase-9 (MMP-9, 1:500, AB19016, Millipore). Blots
were incubated overnight at 4°C with the primary anti-
bodies. After primary antibody incubation, membranes
were washed 3 × 10 min in TBS-T. This was followed by
incubation for 2 h at room temperature with a peroxidase-
conjugated goat anti-rabbit IgG antibody (1:2500) (Jackson
Immuno Research Laboratories, Inc.). The membranes
were washed 3 × 10 min in TBS-T. The immunoreactive
bands were visualized with the ECL enhanced chemilu-
minescence kit (PerkinElmer Inc.) and using Kodak
Biomax XAR imaging film. The immunoreactive bands
were quantified by densitometry of the films using a
MCID M4 image analysis system (Imaging Research Inc.,
St. Catharines, ON, Canada). Membranes were rinsed and
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Sigma) diluted in 5% milk in TBS-T for 1 h at room
temperature, washed with TBS-T, and incubated with a
peroxidase conjugated donkey anti-mouse IgG (1:5000,
Santa Cruz) in 5% dry milk in TBS-T for 1 h. The mem-
branes were washed and the signal was detected and
qualified as described above. The levels of NGF and
MMP-9 were normalized to the β-actin levels for each
sample.
Zymography
Gelatinolytic activity was determined by zymography
using gelatin-containing gels following the protocol pro-
vided by supplier Millipore. The skin samples were col-
lected at the same time point as those for western blot
analysis (see above). The skin sample extracts were
mixed with an equal volume of non-reducing sample
buffer (0.5 M Tris–HCl, pH 6.8, SDS, glycerol and
bromophenol blue). The samples (50 μg of protein) were
electrophoresed on an 8% SDS–PAGE containing 0.1%
gelatin as the substrate. After electrophoretic separation,
the gels were incubated for 30 min in renaturing buffer
(2.5% Triton X-100 in distilled water) to remove the
SDS, washed for 2X10 min with water and then incu-
bated for 24 h at 37°C in a developing buffer containing
50 mM Tris–HCl, pH 7.78; 5 mM CaCl2 and 0.02% Brij
35. Following incubation, the gels were stained for 1 h
with 0.5% Coomassie R-250 staining solution and then
differentiated in a solution of methanol: acetic acid:
water (50 : 10 : 40). Enzyme activity attributed to MMP-
2 and MMP-9 was visualized (on the basis of molecular
weight) in the gelatin-containing zymograms as clear
bands against a blue background. The bands were quan-
tified by densitometry using the MCID M4 image ana-
lysis system.
Immunohistochemistry
Two weeks after the daily injections of MMP-2/9 inhibi-
tor, animals were deeply anesthetized with Equithesin
(6.5 mg chloral hydrate and 3 mg sodium pentobarbital
in a volume of 0.3 mL, i.p., per 100 g body weight) and
then perfused through the left cardiac ventricle with
100 mL of perfusion buffer, followed by 500 mL of 4%
paraformaldehyde (PFA) in 0.1 M phosphate-buffer (PB),
pH 7.4, at room temperature for 30 minutes. Subse-
quently, the plantar glabrous skin was extracted and
post-fixed in the same fixative for 1 hour at 4°C. The tis-
sue was cryoprotected in 30% sucrose in PB overnight at
4°C for later immunohistochemical processing. Fifty-μm
thick cross sections of skin were cut using a cryostat
(Leica, Wetzlar, Germany). All sections were collected as
free-floating in phosphate-buffered saline (PBS) with
0.2% Triton-X 100 (PBS-T). The tissue sections were in-
cubated for 1 hour at room temperature in 10% normalgoat serum (Gibco, Carlsbad, CA) in PBS to block un-
specific labeling. To label the peptidergic and sympa-
thetic fiber populations, the sections were then
incubated at 4°C for 24 hours using either a rabbit anti-
Calcitonin Gene Related Protein (CGRP) (Sigma-
Aldrich, St. Louis, MO, C-8198, lot# 070 M4835, diluted
1:2000) antibody or a rabbit anti-Vesicular Monoamine
Transporter-2 (VMAT-2) (Phoenix Pharmaceuticals,
Inc., CA, USA, H-V004, 01237–1, diluted 1:7500). As
controls, some sections were processed omitting the pri-
mary antibody; no specific staining was observed. After
three rinses in PBS-T, the sections were incubated for
2 hours at room temperature with goat anti-rabbit IgG
conjugated to either Alexa Fluor 488 for CGRP or Alexa
Fluor 594 for VMAT-2 (Molecular Probes, diluted
1:800). For double-labeling of CGRP and VMAT2, sec-
tions were processed as described above except that we
used a guinea pig anti-CGRP antibody at a 1:4000 dilu-
tion (Peninsula, San Carlos, CA, T-5053) in a simultan-
eous incubation with the rabbit anti-VMAT2 antibody;
after washing, we used a mixture of an anti-guinea pig
IgG antibody conjugated to Alexa Fluor 488 (1:800; Mo-
lecular Probes) with the anti-rabbit IgG conjugated to
Alexa Fluor 594. Finally, the sections were washed,
mounted on gelatin-subbed slides, air-dried and cover
slipped with an anti-fading mounting medium (Aqua
PolyMount, Polysciences Inc., Warrington, Pa.). Slides
were stored at 4°C until examined. Since we aimed to
localize and evaluate the morphological changes in in-
nervation and to quantify the relative changes in the im-
munostaining intensity, the conditions of all procedures
(dilutions of reagents and antibodies, washings, incuba-
tion time and temperature, blocking of nonspecific stain-
ing), were kept rigorously throughout the assays and
were identical for the sections from all tested groups.
Within each experiment, immunohistochemical process-
ing of tissue sections sampled from all groups was car-
ried out simultaneously. Before quantitative analyses, all
the slides were coded so that the person who performed
the quantification was completely blinded regarding the
experimental groups. Codes were broken only after the
quantification was completed.
CGRP-immunoreactive fiber quantification
Quantitative analyses were performed on sections of
glabrous skin from the hindpaw ipsilaterally to the injec-
tion of MMP-2/9 inhibitor or vehicle. In this study, as in
previous work from our laboratory, we have divided the
dermis into upper and lower dermis. We have defined
the upper dermis as the area of the dermis spanning
150 μm below the dermal-epidermal junction [37]. For
the measurement of the density of peptidergic fibers, as
detected by CGRP immunoreactivity, we used a Zeiss
Axioplan 2 imaging fluorescence microscope equipped
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microscope has a high resolution digital camera
connected to a computer equipped with the Zeiss
Axiovision 4.8 software (Carl Zeiss, Canada). Three sec-
tions per slide were randomly selected, and 6 micro-
scopic fields including upper dermis were photographed
at random, for a total of 18 images per animal. Images
were exported in the TIFF format for analysis with an
MCID Elite image analysis system (Imaging Research
Inc., St. Catharines, ON, Canada). The upper dermis was
outlined with the use of a tracing tool in the software.
CGRP-IR fibers were automatically detected by the soft-
ware using a brightness threshold and converted to 1
pixel in thickness to compute the total fiber length (μm)
per scan area (μm2).
Sympathetic fiber quantification
We used a different approach to quantify the changes in
autonomic innervation. Since these fibers are much less
abundant in the skin than the sensory, especially in the
upper dermis, it was unpractical to measure fiber dens-
ity. Therefore, we proceeded by photographing 6 entire
skin sections per animal and counting all VMAT-2-IR fi-
bers within the upper dermis, measured to be 150 μm
from the dermal-epidermal junction. The mean number
of fibers in the upper dermis per total area (μm2) was
then calculated.
Data analyses
The Western blot and zymography results represent the
densitometry analyses of all samples (4–6 samples per
group). Inter-group differences were analyzed by one-
way ANOVA and Bonferroni’s multiple comparison tests
(Figures 1 and 2). The mean number of sympathetic fi-
bers and density of sensory peptidergic fibers in the
upper dermis was compared between groups by a one-
way ANOVA and a Dunnett’s post hoc test, with a statis-
tical significance accepted at p <0.05 (Figures 3, 4 and
5). As no significant difference was detected among the
control groups of all time points, they were pooled. The
behavioral data are presented as the mean ± SEM (6–8
animals per group). The effect of single as well as re-
peated intra-plantar injections of MMP-2/9 inhibitor on
mechanical and thermal sensitivity in rats (Figures 6 and
7) was analyzed by one-way analysis of variance
(ANOVA) and Bonferroni’s multiple comparison test.
The effect of repeated injections of MMP-2/9 inhibitor
on allodynia and hyperalgesia was also shown as the area
under the curve (AUC, Figure 7). To evaluate the AUC
the Trapezoidal and Simpson’s Rules, Pharmacologic
Calculation System, version 4.0-03/11/86 was used [86].
Using the GraphPad Prism software, we performed a
correlation analysis between the behavioral responses
and sympathetic fiber sprouting, as this was the onlyfiber population which changed following administration
of the MMP-2/9 inhibitor. The analysis was done on
each behaviorally tested rats from which the skin tissue
was collected for the immunohistochemical component.
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